Measuring meningococcal vaccination coverage among adolescents in Italy: state-of-the-art and regional challenges

Pietro Ferrara 1,2, Luciana Albano 3, Vincenza Gianfredi 4,5

1 Center for Public Health Research, University of Milan – Bicocca, Monza, Italy; 2 IRCCS MultiMedica, Sesto San Giovanni, Milan, Italy; 3 Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy; 4 Department of Biomedical Sciences for Health, University of Milan, Milan, Italy; 5 CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands

To the Editor,

Invasive meningococcal disease (IMD) is a serious infection and major public health problem, with significant health and economic burden due to high morbidity and mortality in children and young adults, as well as extensive consumption of healthcare resource and costs (1,2). The infection is sustained by the bacterium Neisseria meningitidis, with the majority of cases registered in children aged 0 to 4 years and in adolescents aged 15 years or older (1–3), reflecting the importance of including meningococcal vaccines in routine immunization of these subgroups (2,3). At the global level, infections are mostly due to the serogroups A, B, C,W-135, and Y (2), whereas, in Italy, serogroups B and C are the most prevalent, being responsible, in 2019, respectively for 81% and 15% of incident cases in 0–4-year-old children, and 45% and 31% in adolescents and young adults (15–24 years old) (3). The current Italian National Immunization Prevention Plan (PNPV) 2017–2019 offers MenACWY135 to this populations (also to individuals previously with MenC), with coverage goal of 95% of subjects aged 11 to 18 years by 2019 (4). In the previous PNPV (edition 2012–2014), adolescents were offered one dose of MenC vaccine (4), whereas, MenB vaccine value has been proved also from the Italian National Healthcare Service perspective and demanded to regional policies (2,4). Indeed, MenB vaccine is currently offered to adolescents free-of-charge or in co-payment – or is under consideration for the inclusion in vaccination plans – exclusively in some regions, including Campania, Emilia Romagna, Lazio, Liguria, Puglia, Sicily, and others. These differences may drive health inequalities, as well as different level of vaccine coverage.

Here, we analyse current surveillance data on vaccination coverage in adolescents across Italian regions, as crucial information to track vaccination programs’ implementation, and to inform public health policies (5). National and region-stratified vaccination coverage rated are made available through annual reports of the Italian Ministry of Health, and last data available are referred to 2020 (6).

Coverage data for 2020 reports information stratified by two adolescent cohorts, namely 16- and 18-year-old subjects (born in 2004 and 2002, respectively) for both MenC and MenACWY135. The first was administered in 58.6% and 54.0% of the two cohorts, reflecting the importance of including meningococcal vaccines in routine immunization of these subgroups (2,3). At the global level, infections are mostly due to the serogroups A, B, C,W-135, and Y (2), whereas, in Italy, serogroups B and C are the most prevalent, being responsible, in 2019, respectively for 81% and 15% of incident cases in 0–4-year-old children, and 45% and 31% in adolescents and young adults (15–24 years old) (3). The current Italian National Immunization Prevention Plan (PNPV) 2017–2019 offers MenACWY135 to this populations (also to individuals previously with MenC), with coverage goal of 95% of subjects aged 11 to 18 years by 2019 (4). In the previous PNPV (edition 2012–2014), adolescents were offered one dose of MenC vaccine (4), whereas, MenB vaccine value has been proved also from the Italian National Healthcare Service perspective and demanded to regional policies (2,4). Indeed, MenB vaccine is currently offered to adolescents free-of-charge or in co-payment – or is under consideration for the inclusion in vaccination plans – exclusively in some regions, including Campania, Emilia Romagna, Lazio, Liguria, Puglia, Sicily, and others. These differences may drive health inequalities, as well as different level of vaccine coverage.

Here, we analyse current surveillance data on vaccination coverage in adolescents across Italian regions, as crucial information to track vaccination programs’ implementation, and to inform public health policies (5). National and region-stratified vaccination coverage rated are made available through annual reports of the Italian Ministry of Health, and last data available are referred to 2020 (6).

Coverage data for 2020 reports information stratified by two adolescent cohorts, namely 16- and 18-year-old subjects (born in 2004 and 2002, respectively) for both MenC and MenACWY135. The first was administered in 58.6% and 54.0% of the two cohorts, reflecting the importance of including meningococcal vaccines in routine immunization of these subgroups (2,3). At the global level, infections are mostly due to the serogroups A, B, C,W-135, and Y (2), whereas, in Italy, serogroups B and C are the most prevalent, being responsible, in 2019, respectively for 81% and 15% of incident cases in 0–4-year-old children, and 45% and 31% in adolescents and young adults (15–24 years old) (3). The current Italian National Immunization Prevention Plan (PNPV) 2017–2019 offers MenACWY135 to this populations (also to individuals previously with MenC), with coverage goal of 95% of subjects aged 11 to 18 years by 2019 (4). In the previous PNPV (edition 2012–2014), adolescents were offered one dose of MenC vaccine (4), whereas, MenB vaccine value has been proved also from the Italian National Healthcare Service perspective and demanded to regional policies (2,4). Indeed, MenB vaccine is currently offered to adolescents free-of-charge or in co-payment – or is under consideration for the inclusion in vaccination plans – exclusively in some regions, including Campania, Emilia Romagna, Lazio, Liguria, Puglia, Sicily, and others. These differences may drive health inequalities, as well as different level of vaccine coverage.

Here, we analyse current surveillance data on vaccination coverage in adolescents across Italian regions, as crucial information to track vaccination programs’ implementation, and to inform public health policies (5). National and region-stratified vaccination coverage rated are made available through annual reports of the Italian Ministry of Health, and last data available are referred to 2020 (6).

Coverage data for 2020 reports information stratified by two adolescent cohorts, namely 16- and 18-year-old subjects (born in 2004 and 2002, respectively) for both MenC and MenACWY135. The first was administered in 58.6% and 54.0% of the two cohorts, reflecting the importance of including meningococcal vaccines in routine immunization of these subgroups (2,3). At the global level, infections are mostly due to the serogroups A, B, C,W-135, and Y (2), whereas, in Italy, serogroups B and C are the most prevalent, being responsible, in 2019, respectively for 81% and 15% of incident cases in 0–4-year-old children, and 45% and 31% in adolescents and young adults (15–24 years old) (3). The current Italian National Immunization Prevention Plan (PNPV) 2017–2019 offers MenACWY135 to this populations (also to individuals previously with MenC), with coverage goal of 95% of subjects aged 11 to 18 years by 2019 (4). In the previous PNPV (edition 2012–2014), adolescents were offered one dose of MenC vaccine (4), whereas, MenB vaccine value has been proved also from the Italian National Healthcare Service perspective and demanded to regional policies (2,4). Indeed, MenB vaccine is currently offered to adolescents free-of-charge or in co-payment – or is under consideration for the inclusion in vaccination plans – exclusively in some regions, including Campania, Emilia Romagna, Lazio, Liguria, Puglia, Sicily, and others. These differences may drive health inequalities, as well as different level of vaccine coverage.
In the light of the high health and societal burden due to IMDs, the importance of routine vaccination against \textit{N. meningitidis} infection should be enhanced through the research of vaccination hesitancy drivers (13); the inclusion, at national level, of MenB for adolescents and young adults; and the promotion of educational community-based programs designed to improve general public’s awareness and acceptance (14).

In this context, important lessons can be learned from the global fight against COVID-19 emergency (8,15), in which effective and timely vaccination proved to be a crucial strategy for the control of the pandemic (16,17).

All together, these concerns are also part of the Global Vaccine Action Plan developed by the World Health Organization (5), which supports routine vaccination plans and programs, aiming at fighting IMD by 2030.

**Conflicts of interest:** Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article.

**References**

1. Huang L, Heuer OD, Janßen S, Häckl D, Schmedt N. Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database. PLoS ONE 2020;15(1): e0228020. https://doi.org/10.1371/journal.pone.0228020
2. Ferrara P, Stromillo L, Albano L. Awareness, attitudes, and practices toward Meningococcal B vaccine among pediatricians in Italy. Medicina 2018;54(6):100. doi: 10.3390/medicina5406100
3. Istituto Superiore di Sanità. Sorveglianza delle Batteriche Invasive in Italia – Rapporto consolidato 2019. Rome: ISS, 2020.
4. Ministero della Salute. Piano Nazionale della Prevenzione Vaccinale 2017–2019. Roma: Ministero della Salute, 2017.
5. Global Burden of Diseases 2020, Release 1. Vaccine Coverage Collaborators. Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. The Lancet. 2021;398(10299):503-21. doi: 10.1016/S0140-6736(21)00984-3
6. Ministero della Salute. Vaccinazioni dell’età pediatrica e dell’adolescenza - Coperture vaccinali. Available at: https://www.salute.gov.it/portale/documentazione/p6_2_8_3_1.jsp?lingua=italiano&id=20 (last accessed on November 10, 2021)
7. Signorelli C, Odone A, Gianfredi V, et al. The spread of COVID-19 in six western metropolitan regions: a false myth on the excess of mortality in Lombardy and the defense of the city of Milan. Acta Biomed. 2020;91(2):23-30.
8. Balasco N, D’Alessandro V, Ferrara P, Smaldone G, Vitagliano L. Analysis of the time evolution of COVID-19 lethality during the first epidemic wave in Italy. Acta Biomed. 2021;92(2):c2021171.
9. Gianfredi V, Moretti M, Lopalco PL. Countering vaccine hesitancy through immunization information systems, a narrative review. Hum Vaccin Immunother. 2019;15(11):2508-2526. doi: 10.1080/21645515.2019.1599675.
10. Gianfredi V, D’Ancona F, Maraglino F, et al. Polio and measles: reasons of missed vaccination in Italy, 2015-2017. Ann Ig. 2019;31(3):191-201. doi: 10.7416/ai.2019.2282.
11. D’Ancona F, Gianfredi V, Riccardo F, Iannazzo S. Immunization Registries at regional level in Italy and the roadmap for a future Italian National Registry. Ann Ig. 2018 Mar-Apr.;30(2):77-85. doi: 10.7416/ai.2018.2199.
12. Odone A, Gianfredi V, Sorbello S, et al. The Use of Digital Technologies to Support Vaccination Programmes in Europe: State of the Art and Best Practices from Experts’ Interviews. Vaccines 2021; 9:1126.
13. Cella P, Voglino G, Barberis I, et al. Resources for assessing parents’ vaccine hesitancy: a systematic review of the literature. J Prev Med Hyg. 2020;61(3):E340-E373. doi: 10.15167/2955.29706.
14. Gianfredi V, Grisci C, Nucci D, et al. Recenti Prog Med (Communication in health). 2018;109(7):374-383. doi: 10.1007/s11739-021-02857-y.
15. Gianfredi V, Minerva M, Casu G, et al. Immediate adverse events following COVID-19 immunization. A cross-sectional study of 314,664 Italian subjects. Acta Biomed. 2021;92(S6):e2021487. doi: 10.23750/abm.v92iS6.12365.
16. Ponticelli D, Madotto F, Conti S, et al. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up. Intern Emerg Med 2021. doi: 10.1007/s11739-021-02857-y.
17. Vigezzi GP, Lume A, Minerva M, et al. Safety surveillance after BNT162b2 mRNA COVID-19 vaccination: results from a cross-sectional survey among staff of a large Italian teaching hospital. Acta Biomed 2021;92(S6):e2021450.

Received: 1 November 2021 Accepted: 12 November 2021 Correspondence: Vincenza Gianfredi, MD Department of Biomedical Sciences for Health, University of Milan University of Milan Via Pascal, 36 Milan, 20132 Italy E-mail: vincenza.gianfredi@unimi.it